Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIRINOX in Borderline Resectable Pancreatic Cancer
NCT02148549Phase 1Completed
- Sponsor
- Wakayama Medical University
- Start
- Apr 2014
- Primary completion
- Feb 2017
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of oxaliplatin, irinotecan and fluorouracil in pancreatic ductal adenocarcinoma (PDAC), sponsored by Wakayama Medical University. Primary endpoint: Number of participants with toxicity at 30 weeks. Started Apr 2014; status: completed.
02
Drugs
oxaliplatinirinotecanfluorouracil
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02148549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148549.